Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; hyprolose; iron oxide yellow; ethanol absolute; purified water; diacetylated monoglycerides; magnesium stearate; light magnesium oxide; hypromellose phthalate; ethylcellulose; titanium dioxide; carnauba wax; mannitol - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: hyprolose; magnesium stearate; diacetylated monoglycerides; purified talc; ethylcellulose; mannitol; titanium dioxide; light magnesium oxide; carnauba wax; purified water; ethanol absolute; iron oxide red; hypromellose phthalate - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); mannitol; sodium lauryl sulfate; ethylcellulose; polysorbate 80; magnesium stearate; hyprolose; purified talc; iron oxide yellow; povidone; light magnesium oxide; propylene glycol; titanium dioxide - rabeprazole is indicated for: ,? treatment and prevention of relapse of gastro-oesophageal reflux disease ,? symptomatic treatment of gastro-oesophageal reflux disease ,? treatment of duodenal ulcers ,? treatment of gastric ulcers. ,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: ,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis ,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - pantoprazole sodium sesquihydrate, quantity: 45.4 mg (equivalent: pantoprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: mannitol; sodium carbonate; sodium starch glycollate; crospovidone; colloidal anhydrous silica; calcium stearate; hypromellose; macrogol 6000; sodium hydroxide; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - adults 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: ? duodenal ulcer ? gastric ulcer ? gastro-oesophageal reflux disease (gord): - symptomatic gord. the treatment of heartburn and other symptoms associated with gord - reflux oesophagitis ? gastrointestinal lesions refractory to h2 blockers ? zollinger-ellison syndrome patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: ? clarithromycin and amoxicillin or ? clarithromycin and metronidazole or ? amoxicillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see section 4.2 dose and method of administration).,4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism.,5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.,children aged from 5 to 17 years gastro-oesophageal reflux disease (gord) ? symptomatic gord. the treatment of heartburn and other symptoms associated with gord ? reflux oesophagitis the treatment duration should not exceed 8 weeks.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - pantoprazole sodium sesquihydrate, quantity: 22.7 mg (equivalent: pantoprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: mannitol; sodium carbonate; sodium starch glycollate; crospovidone; colloidal anhydrous silica; calcium stearate; hypromellose; macrogol 6000; sodium hydroxide; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - adults 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: ? duodenal ulcer ? gastric ulcer ? gastro-oesophageal reflux disease (gord): - symptomatic gord. the treatment of heartburn and other symptoms associated with gord - reflux oesophagitis ? gastrointestinal lesions refractory to h2 blockers ? zollinger-ellison syndrome patients whose gastric or duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. 3. for eradication of helicobacter pylori, treatment with pantoprazole and one of the following combinations of antibiotics: ? clarithromycin and amoxicillin or ? clarithromycin and metronidazole or ? amoxicillin and metronidazole is recommended in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism (see section 4.2 dose and method of administration).,4. pantoprazole in combination with bismuth, metronidazole and tetracycline is indicated for the eradication of helicobacter pylori associated with peptic ulcer disease with the objective of reducing the recurrence of peptic ulcers caused by this organism.,5. prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective non-steroidal anti-inflammatory drugs (nsaids) in increased risk patients with a need for continuous non-selective nsaid treatment.,children aged from 5 to 17 years gastro-oesophageal reflux disease (gord) ? symptomatic gord. the treatment of heartburn and other symptoms associated with gord ? reflux oesophagitis the treatment duration should not exceed 8 weeks.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: ethylcellulose; iron oxide yellow; mannitol; diethyl phthalate; hypromellose phthalate; sodium starch glycollate type a; light magnesium oxide; magnesium stearate; titanium dioxide; purified talc; povidone - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: sodium starch glycollate type a; diethyl phthalate; purified talc; povidone; titanium dioxide; iron oxide red; hypromellose phthalate; ethylcellulose; magnesium stearate; light magnesium oxide; mannitol - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: mannitol; magnesium stearate; diethyl phthalate; ethylcellulose; hypromellose phthalate; purified talc; iron oxide yellow; light magnesium oxide; povidone; sodium starch glycollate type a; titanium dioxide - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: light magnesium oxide; purified talc; diethyl phthalate; povidone; hypromellose phthalate; titanium dioxide; magnesium stearate; mannitol; sodium starch glycollate type a; ethylcellulose; iron oxide red - rabeprazole is indicated for: - treatment and prevention of relapse of gastro-oesophageal reflux disease. - symptomatic treatment of gastro-oesophageal reflux disease. - treatment of duodenal ulcers. - treatment of gastric ulcers. patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal anti-inflammatory drugs (nsaids) usually require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. rabeprazole is also indicated, in combination with clarithromycin and amoxycillin, for: - eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis. - healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - esomeprazole magnesium, quantity: 41.4 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: macrogol 400; hypromellose phthalate; macrogol 6000; diethyl phthalate; microcrystalline cellulose; crospovidone; hyprolose; sodium stearylfumarate; povidone; purified talc; macrogol 4000; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer